Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…
Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial
Forlong Biotech has completed the second close of its Pre-B financing, bringing the round’s total to nearly RMB 200 million. Fosun Health Capital’s new drug fund led the latest close, which raised more than RMB 100 million, according to Chinese financing…
ByteDance’s AI Drug Discovery Spinout Anew Labs Reportedly Raises $290 Million
Anew Labs, the AI drug discovery company spun out of TikTok owner ByteDance, has reportedly completed a $290 million first independent financing round. China’s PEdaily reported the raise citing sources; Reuters separately reported the same amount based…
Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
Hangzhou-based Unike Biopharma has completed an angel financing round worth tens of millions of RMB, giving the young biotech fresh capital to advance a broad pipeline of long-acting protein and peptide therapeutics built around its proprietary ZT…
Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Lumiere Therapeutics has raised more than RMB 100 million (approximately $14 million) in a Pre-A financing round, giving the Chinese gene-editing company fresh capital to push its epigenetic editing programs toward the clinic. The financing was co-led by…
AIPher Raises ~RMB 100 Million Angel Round to Build AI-Native Drug Discovery Platform
Chinese AI-driven drug discovery startup AIPher has completed an angel financing round of approximately RMB 100 million (about $14 million+), an unusually large early-stage raise completed just over a month after the company was established. The…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…
Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline
Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…